Bavare Aarti C, Naik Swati X, Lin Peter H, Poi Mun Jye, Yee Donald L, Bronicki Ronald A, Philip Joseph X, Desai Moreshwar S
Section of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Ann Vasc Surg. 2014 Oct;28(7):1794.e1-7. doi: 10.1016/j.avsg.2014.03.016. Epub 2014 Mar 31.
Catheter-directed thrombolytic (CDT) therapies for severe pulmonary embolism (PE) have been shown to be effective and safe when compared with systemic thrombolysis in adults. Pediatric studies assessing efficacy and safety of CDT for PE are lacking. Hence, our aim was to review CDT as a therapy for pediatric PE.
We retrospectively reviewed charts of patients aged <18 years, who underwent CDT for main or major branch pulmonary artery occlusion associated with hypotension or right ventricular dysfunction secondary to PE during a 3-year period, in our tertiary care academic Pediatric Intensive Care Unit.
Six CDT interventions were performed on 5 patients with PE (median age: 16.5 years). All patients presented with chest pain and dyspnea. The predisposing factors for thrombogenesis differed in all patients, and all had multiple risk factors. Five of six procedures (83%) were accompanied by ultrasound agitation with EKOS endowave infusion system (ultrasound-accelerated CDT [UCDT]), whereas 1 had CDT without ultrasound agitation. Complete resolution of PE occurred in 4 instances (67%) at 24 hr, whereas in 2 cases (33%), there was partial resolution. One patient with complete resolution underwent another successful UCDT after 4 months for recurrence. Clinical parameters (heart rate, respiratory rate, blood pressure, and oxygen saturations) and echocardiographic findings improved after treatment in all the patients. Median duration of hospital stay was 9 days with no mortality and treatment-related complications. All patients were discharged with long-term anticoagulation.
Our case series is the first that describes CDT/UCDT as an effective and safe therapy for pediatric patients with severe PE. CDT is known to accelerate fibrinolysis via focused delivery of thrombolytic agent to the thrombus site. For carefully selected patients, CDT/UCDT provides a useful treatment option for severe PE irrespective of the etiology, predisposing conditions, and associated comorbidities.
与成人系统性溶栓相比,导管定向溶栓(CDT)治疗严重肺栓塞(PE)已被证明是有效且安全的。目前缺乏评估CDT治疗PE疗效和安全性的儿科研究。因此,我们的目的是回顾CDT作为儿科PE的一种治疗方法。
我们回顾性分析了在我们三级医疗学术儿科重症监护病房3年期间,年龄小于18岁、因PE继发低血压或右心室功能障碍而接受CDT治疗主肺动脉或主要分支肺动脉闭塞的患者病历。
对5例PE患者(中位年龄:16.5岁)进行了6次CDT干预。所有患者均出现胸痛和呼吸困难。所有患者血栓形成的诱发因素各不相同,且均有多种危险因素。6次操作中有5次(83%)伴有使用EKOS endowave输注系统的超声搅动(超声加速CDT [UCDT]),而1次为无超声搅动的CDT。4例(67%)患者在24小时时PE完全溶解,而2例(33%)部分溶解。1例完全溶解的患者在4个月后因复发再次成功接受UCDT治疗。所有患者治疗后临床参数(心率、呼吸频率、血压和血氧饱和度)及超声心动图结果均有改善。中位住院时间为9天,无死亡及治疗相关并发症。所有患者出院时均接受长期抗凝治疗。
我们的病例系列是首个将CDT/UCDT描述为治疗严重PE儿科患者有效且安全的疗法。已知CDT可通过将溶栓剂聚焦输送至血栓部位来加速纤维蛋白溶解。对于精心挑选的患者,无论病因、诱发条件及相关合并症如何,CDT/UCDT为严重PE提供了一种有用的治疗选择。